Share
2,450 Posts.
lightbulb Created with Sketch. 394
clock Created with Sketch.
22/04/17
20:10
Share
Originally posted by lexcorp
↑
Hi iceman
I don't know man. I'm sure it would incur decent costs to list there and maintain it. I have seen it done elsewhere such as a few other asx company's and haven't seen it make a difference for the company.
I don't know for sure but I'd like to think bringing in WP was a long term view and not just a fluke but you never know the connections these directors have.
I think WP is an astute operator. Whether he has timed things well by saying no more tapping of the market while he is operating the company along with talks the company may project could bring in a deal with a large pharma etc must be confidence in his ability/cycle of the company's prospects?
Hard to put it into words for myself
I like his outlook and leadership no doubt there. He is finding low hanging fruit such as tavr prototype and with surgeons demands other adapt products.
Quick income generators
Targeting worthy prOducts
Still early and a long road ahead will reveal his plans on the bottom line
So far so good though
We have to trust his experience and knowledge though. His plan is made and no mention of any other listing
I've contacted him and offered a company he and I have interests in and he has said there's better opportunities within the company's current divisions to return better gains for holders
Only time will tell
Even at net tangible assets he has knocked back my suggestion
I can only trust him and have faith
For me either we're in for the long haul with patience or holding a dud but I believe in the divisions we have as you would too given we have such class in CC/adapt, Frazer and his expertise and a cash generator in the infusion med supply business.
We all I think want to have the announcements we long for but have to put back our enthusiasm and wants for the long term goals which as you understand takes a long time
Rough and tough but worthy
We have probably the best chance of really being a great company than many other med/bio stocks
At least in the top few available in the market I reckon
I'd say a lot of the investment community see the risk in finding the work being done in HSV especially high risk and imo HPV lesser of a risk due to Frazers exp
Cc is just about penetration now with the top 4 competitors having recalls and we are gaining market share slowly as probably as realistically expected even though we're all having too high of an expectation I think
I think we are al guilty of not comprehending the time things take
I've been thinking who our suitors could be to partner with too
Check point inhibitors are probably the most sought after thing ATM
Many deals coming online
Weed them out and we might uncover our dancing partners
I reckon we could research into it to eliminate already taken paired up players but there is so many
Big bloody companies too
These check point inhibitors are all the rage I've found
Sometimes I also think if I call someone they just give you a quick answer thinking you don't know any different
So far WP I've found to be straight up
Cheers
Expand
Thank you lex, respect your confidence and the content of your post.
Great to see investors attempting to read in between the lines rather than relying 100 per cent on what the company's says, sure you would agree that it makes for pragmatic investing.
Out of curiosity, 'repeating' myself again ... lol, have you any other company on your radar in Ahz s position? That is : 'great potential' but very poor sp/sentiment for such a long time?
Would investors from the US not be aware of the developments of Ahz and invest or take over the company especially if already willing to invest in companies in the States in the scenario we talked about? Larger losses, lesser different IP etc?